Drug Trial Radar · NCT04492033
A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients
Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
41
Actual
Start
Jun 22, 2020
Primary completion
Jan 8, 2024
Study completion Jan 9, 2025
Sponsor
- Lead sponsor
- Handok Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Compass Therapeutics; ABL Bio, Inc.
- First posted
- Jul 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase 1b/2 multi-center study to assess the safety, tolerability, pharmacokinetics of CTX-009 (ABL001) in combination with Irinotecan or Paclitaxel in patients with advanced or metastatic solid tumors.
Conditions
- P1b: Advanced Solid Tumors
- P2: Biliary Tract Cancer
Interventions
CTX-009 (ABL001)Drug
CTX-009 (ABL001) will be administered biweekly.
PaclitaxelDrug
Paclitaxel will be administered weekly.
IrinotecanDrug
Irinotecan will be administered biweekly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- P1b: Proportion of subjects with Dose-Limiting Toxicity (DLT)Time frame: From Day 1 until disease progression or Day 28, whichever came first
- P2: Objective response rate (ORR) of CTX-009 (ABL001) in combination with paclitaxel in patients with BTCTime frame: Up to approximately 24 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.